About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Risedronate in Postmenopausal Women With Low Bone Density

Risedronate in Postmenopausal Women With Low Bone Density

NCT00351091·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Sanofi

With

Procter and Gamble

Age

65–80

Sex

FEMALE

Healthy volunteers

Not accepted

You may be eligible if

ambulatory women,postmenopausal \>= 5 years
have lumbar spine baseline BMD within the following criterion :
* Hologic: \<= 0.827 g/cm2 or
* Lunar: \<= 0.942 g/cm2 or
* Norland: \<= 0.768 g/cm2
be in general good health as determined by medical history, physical examination and laboratory tests

You may not be if

serum 25-OH vitamin D level \<= 12 ng/ml
history of osteomalacia
history of active hyperparathyroidism or hyperthyroidism
hypocalcemia or hypercalcemia from any cause
depot injection \>10,000 IU Vitamin D in the past 9 months prior to starting the investigational product
use of Vitamin D supplementation within 3 months prior to starting the investigational product
use of any of the following medications within a specified number of months prior to starting the investigational product :
* any bisphosphonate.
* use of any fluoride with the exception of fluoride use for oral hygiene
* strontium
* other bone active agents
* subcutaneous estrogen implant
* oral or parenteral glucocorticoids
* anabolic steroids
* estrogen or estrogen-related drugs, except for low dose vaginal creams
* progestogen
* calcitonin, calcitriol, or calcifediol
any allergic or abnormal reaction to bisphosphonates
creatinine clearance \< 30 ml/min

The record

StatusCompleted

PhasePhase 2

Taking part150

StartedNov 2002

UpdatedFeb 17, 2012

Conditions

OSTEOPOROSIS, POSTMENOPAUSAL